NCT04927195View on ClinicalTrials.gov

Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Atopic DermatitisPsoriasisAsthma
Interventions
DRUG

EDP1867

EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

DRUG

Placebo

Placebo oral capsule

Trial Locations (7)

M13 9NQ

MAC Clinical Research Manchester, Manchester

M23 9QZ

Medicines Evaluation Unit (MEU), Manchester

FY2 0JH

MAC Clinical Research, Blackpool

L34 1BH

MAC Clinical Research, Liverpool

WS11 0BN

MAC Clinical Research, Cannock

TS17 6EW

MAC Clinical Research, Stockton-on-Tees

LS10 1DU

MAC Clinical Research, Leeds

Sponsors
All Listed Sponsors
lead

Evelo Biosciences, Inc.

INDUSTRY

NCT04927195 - Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma | Biotech Hunter | Biotech Hunter